Online inquiry

IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8134MR)

This product GTTS-WQ8134MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ8134MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3220MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ1608MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ2186MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ10761MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-6495
GTTS-WQ2563MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 479
GTTS-WQ2835MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-403
GTTS-WQ11080MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MCS-110
GTTS-WQ2042MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AHLX-20
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW